| Literature DB >> 15780727 |
Stephen A Kaba1, Anthony J Musoke, Dick Schaap, Theo Schetters, John Rowlands, Arno N Vermeulen, Vishvanath Nene, Just M Vlak, Monique M van Oers.
Abstract
Two novel baculovirus-derived recombinant Theileria parva p67 constructs were tested for their vaccine potential against East Coast fever. Boran calves were immunized with a his-GFP-p67 fusion protein (GFP:p67deltaSS) or with GP64:p67C, a protein fusion between a C-terminal domain of p67 and the baculovirus envelope protein GP64. Both GFP:p67deltaSS and GP64:p67C induced antibodies with high ELISA titers that neutralized T. parva sporozoites with high efficiency. Upon challenge, a correlation was observed between the in vitro neutralizing capacity and the reduction in severe ECF for individual animals. A protection level upto 85% was obtained. This level of protection was achieved with only two inoculations of 100 microg per dose, which is a major improvement over previous recombinant p67 products.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15780727 DOI： 10.1016/j.vaccine.2004.10.043
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641